Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13

Larimar Therapeutics, Inc. (NASDAQ:LRMR)  is one of the 10 Small–Cap Stocks Insiders Are Buying Recently.

On March 20, 2026, Wedbush raised the price target on Larimar Therapeutics, Inc. (NASDAQ:LRMR) to $13 from $12 previously and maintained an Outperform rating. Wedbush said the Q4 update was in line with expectations as the company prepares for its nomlabofusp regulatory submission in June 2026, noting management reiterated a cash runway into Q2 2027 following recent financing, while near-term focus is on updated open-label data expected in Q2.

On March 19, 2026, Larimar Therapeutics, Inc. (NASDAQ:LRMR) reported Q4 EPS of (73c), compared to the (55c) consensus estimate. As of December 31, 2025, the company had $136.9M in cash, cash equivalents, and marketable securities, along with $107.6M in net proceeds from a February 2026 public offering, supporting a projected cash runway into Q2 2027. Chief Executive Officer Carole Ben-Maimon said the company is advancing nomlabofusp toward registration, highlighting “Breakthrough Therapy Designation” and ongoing FDA engagement, while noting plans to submit a Biologics License Application in June 2026 and report topline data from an open-label study in Q2.

Pixabay/Public Domain

Larimar Therapeutics, Inc. (NASDAQ:LRMR) develops treatments for rare diseases using its cell-penetrating peptide technology platform.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.